Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
7
×
biotech
boston blog main
life sciences
national
national blog main
national top stories
raleigh-durham blog main
raleigh-durham top stories
7
×
san francisco blog main
san francisco top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
clinical trials
novartis
astrazeneca
europe blog main
europe top stories
fda
glaxosmithkline
allergan
amgen
boehringer ingelheim
covid-19
What
bio
roundup
abbvie’s
acquisitions
cancer
ceo
daniel
day
days
debut
gilead
ipo
labor
life
moves
opioid
o’day
science
sciences
week
ahead
announced
august
barbecuing
biggest
biofourmis
biotech
black
blood
broader
bucks
build
busy
buy
camping
cardiologist
celebrate
center
chance
check
Language
unset
7
×
Current search:
abbvie
×
unset
×
" raleigh-durham top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
